drugset
drugset / Trial / NCT00481169

Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women

NCT00481169 ↗

Phase 3 Completed 1742 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether TSE-424 (bazedoxifene acetate), an investigational drug, is safe and effective in the prevention of osteoporosis in postmenopausal women.

Timeline

Start
2001-07
Primary completion
2004-07
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified — —

Indications

osteoporosis